20th June, 2017

James Egan and five friends are preparing to start the nine-day, 1600km 'Ride for Beth' on Friday
James Egan, the chief commercial officer at ABN Amro Clearing, and a group of friends are planning to ride 1600km through Europe in just nine days to fund a programme to research a rare auto immune disease called Linear Scleroderma.
Egan and his friends will begin the ‘Ride for Beth’, named after James’ daughter who has the disease, on June 23 in London and plan to ride through France, Belgium, Luxembourg, Germany, Switzerland before arriving in Venice on July 1.
The group plans to raise at least £150,000 (but ideally a lot more) to set-up a programme at London’s Great Ormond Street Hospital to work to better understand the condition and its prevention, and to ultimately find a cure for Scleroderma.
‘Ride for Beth’ is the sole source of finance for this programme which Egan said has as its goal “to prevent other families going through our experience”.
Linear Scleroderma is a rare condition caused by the body’s immune system attacking the tissue under the skin and around internal organs and blood vessels.
Beth, who is ten years old, was diagnosed with Linear Scleroderma in 2015 and has for the past 17 months been undergoing various treatments for a localised form of the disease.
To read more about Beth, Linear Scleroderma and to donate to ‘Ride for Beth’, please visit James’ webpage at: www.virginmoneygiving.com/team/teambeth
1st September, 2026
The former FICC technology executive will lead the firm's global engineering organisation and its data and artificial intelligence strategy.
Zak Jakubowski

1st September, 2026
The World Federation of Exchanges (WFE) said prudential reforms should recognise the risk-reducing benefits of central clearing and preserve a separate framework for investment firms.
Zak Jakubowski

1st September, 2026
The partnership will initially offer products linked to US Federal Reserve rate decisions, with the securities expected to list on Euronext Italy.
Zak Jakubowski
